TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

Ian W Flinn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.